DexCom's stock narrative has shifted as analysts lower their fair value estimate from $98.40 to $84.96, marking a significant downward revision in the price target. This adjustment is primarily driven ...
Dexcom has obtained an FDA clearance for its basal insulin dosing optimizing program, designed for adults with Type 2 diabetes using its continuous glucose monitors. | Dexcom said Smart Basal is the ...
Dexcom Inc. received U.S. FDA clearance for its Smart Basal CGM-integrated basal insulin dosing optimizer. Designed for adults with type 2 diabetes using glargine U-100 long-acting insulin therapy, ...
Today, prominent investor rights law firm Bernstein Litowitz Berger & Grossmann LLP ("BLB&G") filed a class action in the U.S. District Court for the Southern District of New York alleging violations ...
Q3 2025 Earnings Call Transcript October 30, 2025 DexCom, Inc. beats earnings expectations. Reported EPS is $0.61, expectations were $0.57. Operator: Ladies and gentlemen, welcome to the DexCom Third ...
DexCom (DXCM) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2025. This widely-known consensus outlook gives a ...
StockStory.org on MSN
3 Reasons We’re Fans of DexCom (DXCM)
What a brutal six months it’s been for DexCom. The stock has dropped 32.6% and now trades at $58.63, rattling many ...
Aristotle Atlantic Partners, LLC, an investment advisor, released its “Core Equity Strategy” third-quarter 2025 investor ...
Dexcom Inc. executives may have thought a $30 million beat of the consensus estimates for third quarter revenue and 20% growth year-over-year provided a treat to shareholders, but investors seemed to ...
Dexcom (NSDQ:DXCM) announced today that the FDA cleared its Smart Basal CGM-integrated basal insulin dosing optimizer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback